INTRODUCTION AND OBJECTIVES: Progression-free survival (PFS) of first-line targeted therapy (TT) greatly influences on the survival of patients with metastatic renal cell carcinoma (RCC). If we can predict disease progression early after an administration of first-line TT, we may be able to choose appropriate targeted agent (TA) for individual patients. In the present study, we evaluated whether posttreatment inflammatory marker and LDH levels had adoptive impacts on PFS prediction in addition to conventional prognostic factors.
INTRODUCTION AND OBJECTIVES: Progression-free survival (PFS) of first-line targeted therapy (TT) greatly influences on the survival of patients with metastatic renal cell carcinoma (RCC). If we can predict disease progression early after an administration of first-line TT, we may be able to choose appropriate targeted agent (TA) for individual patients. In the present study, we evaluated whether posttreatment inflammatory marker and LDH levels had adoptive impacts on PFS prediction in addition to conventional prognostic factors.
METHODS: In this multi-institutional study 325 patients with metastatic RCC were enrolled from 8 institutions. Of these patients 215 patients whose tumors were diagnosed as clear cell type and in whom first-line TAs could be continued for more than 1 month, were selected (median follow-up period: 20.6 mo). Pretreatment clinical factors, pathological factors, and laboratory data 1 month after TA administration including inflammatory markers [neutrophil count, neutrophilto-lymphocyte rate (NLR) and C-reactive protein (CRP)] and lactate dehydrogenase (LDH), were reviewed. To identify predictors for PFS, univariate and multivariate analyses were done by cox proportional hazards model. RESULTS: Six TAs were used as first-line TT. Tyrosine kinase inhibitors were used for 205 patients and mTOR inhibitors for 10 patients. Nephrectomy was done for 184 patients and percutaneous needle biopsy was done for the diagnosis in 31 patients. MSKCC risk criteria was favorable in 62 patients, intermediate in 122, poor in 17, not determined in 14. The 1-year PFS rate was 47%. Univariate analysis showed that female patients, Karnofsky performance status (KPS) <80%, sarcomatoid differentiation, time from diagnosis to systemic treatment <12 months, anemia, thrombocytosis, pretreatment neutrophil count >upper limits of normal (ULN), pretreatment LDH >1.5 x ULN, LDH 1 month after TT (LDH-1M) >1.5 x ULN, pretreatment NLR >3.7, NLR 1 month after TT (NLR-1M) >3.0, pretreatment CRP >3.0 mg/dL, and CRP 1 month after TT (CRP-1M) >1.5 mg/dL, were significantly associated with PFS. In contrast, LDH decline 1M after TT, decline in neutrophil count 1M after TT, CRP decline 1M after TT, and NLR decline 1M after TT, were not significant factor even in univariate analyses. In multivariate analysis, female, KPS <80%, time from diagnosis to systemic treatment <12M, pretreatment CRP >3.0, and NLR-1M >3.0 were independent predictors for PFS. When all patients were stratified to 3 groups by these 5 factors (0 risk vs. 1 or 2 risks vs. 3 risks or more), there were significant differences in PFS rates between the groups (p<0.0001). The median time to progression was 27.6 months in 0 risk, 10.0 months in 1 or 2 risks, and 2.8 months in 3 or more risks. Furthermore, when we looked at overall survival (OS), there were also significant differences in OS rates between the groups (p<0.0001). The median OS was 58.5 months in 0 risk, 33.5 months in 1 or 2 risks, and 7.6 months in 3 or more risks.
CONCLUSIONS: Integration of NLR-1M >3.0 to pretreatment factors may lead to the establishment of effective predictive models for disease progression in patients with metastatic clear cell RCC who receive targeted argents. The absolute value of NLR appeared to be more important for PFS prediction compared to the NLR decline 1 month after targeted therapy.
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Ryoma Igarashi*, Akita, Japan; Norihiko Tsuchiya, Yamagata, Japan; Takamitsu Inoue, Nobuhiro Fujiyama, Kazuyuki Numakura, Hiroshi Tsuruta, Hideaki Kagaya, Atsushi Maeno, Mitsuru Saito, Shintaro Narita, Takenori Nioka, Masatomo Miura, Shigeru Sato, Tomonori Habuchi, Akita, Japan INTRODUCTION AND OBJECTIVES: Axitinib is approved for use in a second-line therapy for metastatic renal cell carcinoma (mRCC). The predictions of adverse events and efficacy may contribute to the development of personalized medicine. In this study, axitinib pharmacokinetics were analyzed, and the relationships between genetic polymorphisms, the frequency of adverse events, objective responses, and survival were evaluated.
METHODS: A total of 53 patients with mRCC treated with axitinib were analyzed. High-performance liquid chromatography was used to measure the serum axitinib levels. AUC0e12 (ng$h/mL) was calculated using the serum levels at 0, 2, 4, 8, and 12 h following administration (C0, C2, C4, C8, C12, respectively; ng/mL) on day 7 of the treatment. The genetic polymorphisms related to the drug pharmacokinetics, including SLCO1B1, SLCO1B3, SLCO2B1, ABCB1, ABCG2, CYP2C19, CYP3A5, and UGT1A1, were analyzed using PCR-RELP.
RESULTS: The axitinib trough levels (C0) were significantly correlated with AUC0e12 of axitinib. The mean C0 and AUC0e12 values in patients with UGT1A1 polymorphism of a poor metabolizer (*6/*6, *6/*28, and *28/*28) were significantly higher than in those with UGT1A1 polymorphism of an extensive metabolizer (*1/*1, *1/*6, *1/ *28, *27/*28; p ¼ 0.045 and P ¼0.035, respectively). The mean AUC0e12 value in patients with SLCO1B1 *15 was significantly higher than that in those without (p ¼ 0.038). The incidence of hand-foot syndrome ¼ G2, hypothyroidism ¼ G2, increased aspartate aminotransferase ¼ G1, and increased alanine aminotransferase ¼ G1 in patients with C0 ¼ 10 ng/mL were significantly higher than that in those with C0 < 10 ng/mL (p ¼ 0.013, P ¼ 0.005, P ¼ 0.037, and P ¼ 0.005). The overall survival in patients with C0 ¼ 5 ng/mL was significantly better than that in those with C0 < 5 ng/mL (p ¼ 0.022).
CONCLUSIONS: The UGT1A1 and SLCO1B1 were significantly associated with serum axitinib levels. Axitinib trough levels predict therapeutic response in patients with mRCC. The optimal trough level of axitinib may be 5 to 10 ng/mL to achieve an effective treatment without severe adverse events.
